These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32458310)

  • 1. Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
    Zhang JY; Li L; Liu W; Jin Y; Zhao M; Zhou Y; Fan Z
    Clin Transl Oncol; 2021 Jan; 23(1):48-57. PubMed ID: 32458310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
    Zhang JY; Yu K; Li LJ
    Clin Transl Oncol; 2019 Nov; 21(11):1543-1550. PubMed ID: 30915633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
    Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
    Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
    Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
    Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
    Lei M; Liu L; Wang Z; Wu D
    Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
    Wang J; Jiang B; Jiang Q; Lu J; Zhu HH; Yang SM; Zhao T; Wen L; Bao L; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):194-200. PubMed ID: 27033755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
    Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
    Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
    Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.